gallery 07 · about the project
About Medicine Wolverine
An independent editorial gallery of the published BPC-157 TB-500 record — and an explicit account of what this project is and is not.
What this project is
Medicine Wolverine is an independent editorial project that publishes summaries of the peer-reviewed research literature on BPC-157 TB-500 — the two-peptide research blend pairing BPC-157 with TB-500. We are not a clinic. We do not employ clinicians, and we do not provide medical advice. We do not manufacture, sell, or distribute any product. Our work is editorial commentary on publicly available science.
The site is built as a gallery for a reason. The blend's evidence is a heterogeneous collection drawn from two separate constituent literatures — a tendon study, an angiogenesis finding, an actin crystal structure, a human safety dataset, a pharmacokinetic profile — with no controlled combination trial binding them. A gallery is the honest vessel for that: it presents the record study by study, each item tagged with which leg of the blend it belongs to and what its evidence status is, rather than pretending a single coherent dataset exists.
What 'medicine' means in the name
The word "medicine" in this site's name is editorial framing — a position the publisher takes toward the literature and toward the question of medicinal access, not a claim about services we offer. We do not run a clinic, a pharmacy, or a telehealth practice. We do not diagnose, treat, prescribe, or consult. What "medicine" signals here is the register we read in: alongside the research, we surface where medicinal access actually stands — the FDA 503A compounding status, the WADA position, and the regulatory landscape — as documented, cited facts. That is the distinction this page draws explicitly, so it is not mistaken for anything else.
How we handle the evidence
Every quantitative claim on this site cites a specific study, and the references page lists each one with its DOI and source link. Where the data is precise — BPC-157's elimination half-life under 30 minutes in animal pharmacokinetics [5], the one-to-one actin binding resolved by crystallography [3] — we state it precisely. Where it is absent — no controlled combination trial, no validated blend dose, no human data for the TB-500 heptapeptide itself [8][9] — we state that just as plainly. We do not present community protocols as validated dosing, and we use only generic compound names. The editorial posture is simple: the published record, read first, and the gaps named as clearly as the findings.